These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8484654)

  • 21. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
    Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
    Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
    Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
    Chew PT; Aung T; Aquino MV; Rojanapongpun P;
    Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
    Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combination of levobunolol and dipivefrin for the treatment of glaucoma.
    Allen RC; Robin AL; Long D; Novack GD; Lue JC; Kaplan G
    Arch Ophthalmol; 1988 Jul; 106(7):904-7. PubMed ID: 3291837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Local subjective tolerance of levobunolol and metipranolol in a double-blind comparative study in patients with increased intraocular pressure].
    Ober M; Scharrer A; Novack GD; Lue JC
    Ophthalmologica; 1986; 192(3):159-64. PubMed ID: 2873545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Local anesthetic effect and subjective tolerance of 0.5% levobunolol in normal eyes].
    Höh H
    Klin Monbl Augenheilkd; 1990 Jul; 197(1):20-6. PubMed ID: 2203934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular and cardiac beta-antagonism by timolol prodrugs, timolol and levobunolol.
    Potter DE; Shumate DJ; Bundgaard H; Lee VH
    Curr Eye Res; 1988 Aug; 7(8):755-9. PubMed ID: 2903009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-response study of the effect of levobunolol on ocular hypertension.
    Partamian LG; Kass MA; Gordon M
    Am J Ophthalmol; 1983 Feb; 95(2):229-32. PubMed ID: 6337497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of timolol maleate and levobunolol: doses and volume per bottle.
    Schwartz JS; Christensen RE; Lee DA
    Arch Ophthalmol; 1989 Jan; 107(1):17. PubMed ID: 2642700
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of one week of levobunolol HCl 0.5% on the human retinal circulation.
    Bloom AH; Grunwald JE; DuPont JC
    Curr Eye Res; 1997 Mar; 16(3):191-6. PubMed ID: 9088734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of levobunolol eyedrops in healthy subjects.
    Weiser BA; Feldman F; Ananthanarayan CR; Gilbert BW; Haq A
    Can J Ophthalmol; 1991 Jun; 26(4):211-4. PubMed ID: 1889023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levobunolol levels following topical administration with reference to systemic side effects.
    Novack GD; Tang-Liu DD; Kelley EP; Liu SS; Shen CD; Duzman E
    Ophthalmologica; 1987; 194(4):194-200. PubMed ID: 3306546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist.
    Woodward DF; Novack GD; Williams LS; Nieves AL; Potter DE
    J Ocul Pharmacol; 1987; 3(1):11-5. PubMed ID: 2903201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a beta-blocker on altered body position: induced ocular hypertension.
    Smith DA; Trope GE
    Br J Ophthalmol; 1990 Oct; 74(10):605-6. PubMed ID: 2285683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.